| Literature DB >> 33936749 |
Alex J Berry1, Sarah Wiethoff2.
Abstract
We report a case of a 62-year-old female diagnosed with functional neurological disorder (FND), where the diagnosis was eventually revised to progressive supranuclear palsy 3 years after symptom onset. FND is a commonly encountered condition and can be diagnosed with a considerable degree of confidence in most cases. FND is associated with significant functional impairment and may occur alongside other neurological disorders, and there is now a growing evidence base for symptom-specific FND treatments. Charting clinical progression of symptoms and serial neuroimaging were useful in refining the diagnosis in this case. Alhough the diagnosis was ultimately revised to a neurodegenerative disorder, a degree of functional overlay likely remained present. The case highlights the importance of recognizing and avoiding diagnostic overshadowing in those with FND.Entities:
Year: 2020 PMID: 33936749 PMCID: PMC8060990 DOI: 10.1093/omcr/omaa073
Source DB: PubMed Journal: Oxf Med Case Reports ISSN: 2053-8855
Figure 1T2-weighted MRI scan showing normal appearances 1 year after symptom onset.
Figure 2Susceptibility-weighted MRI scan showing hypointense signal within the bilateral globi pallidi, 3 years after symptom onset.
Summary of investigations: normal values are within brackets.
| Investigation | Results |
|---|---|
| Full blood count | Haemoglobin 103 (115–155 g/L), haematocrit 0.329 (0.33–45 L/L), mean corpuscular haemoglobin 313 (320–360 g/L), mean corpuscular volume 103.1 (80–99 fL), white cell count and platelets within normal ranges |
| Renal function | eGFR 34 ml/min, creatinine 140 (49–92 μmol/L), urea 17.7 mmol/L, sodium and potassium within normal limits |
| Liver function tests | Alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase and albumin within normal ranges |
| Iron studies | Ferritin 306 μg/L (13–150 μg/L), iron 12.8 (6.6–26 μmol/L), total iron-binding capacity 58 (41–77 μmol/L), iron-binding saturation 22% (15–50%) |
| Caeruloplasmin | 0.22 g/L (normal range 0.16–0.45 g/L) |
| MRI brain | Hypointensity of the substantia nigra, red nuclei and globus pallidus on SWI sequence |
| CT head | No intracerebral calcification |
| DaTscan | Marked reduction in tracer binding bilaterally |
| Electromyography and electroencephalography | Subcortical negative myoclonus and polyminimyoclonus when attempting to flex upper limbs against force |
| Autonomic testing | Normal basal plasma catecholamines, no evidence of cardiovascular failure, and preserved responses to cold |
| Genetic testing | No pathogenic mutations identified within the following: |
| Neuropsychometric testing | Slowed performances on tests of attention and processing speed, suggesting mild anterior and subcortical dysfunction |
eGFR, estimated glomerular filtration rate; CT, computed tomography.
Figure 3DaTscan results showing reduced [123I] FPCIT tracer uptake bilaterally, 3 years after symptom onset.